BIBLIOGRAFÍA

SECCIÓN A.
Principios generales

CAPÍTULO 1.
Origen y evolución de las enfermedades infecciosas

1. Black, F.L.: Infectious diseases in primitive societies. Science, 1975, 187: 55.
2. Butler CD. Climate Change, Health and Existential Risks to Civilization: A Comprehensive Review (1989-2013). Int J Environ Res Public Health. 2018; 15(10).
3. Cockburn, T.A.: Where did our infectious diseases arise? En: "Health and Disease in Tribal Societies". Ciba Foundation Symposium 49. Amsterdam, Elsevier, 1977, p. 103.
4. Colwell, R.R.: Global climate and infectious diseases. The cholera paradigm. Science 1996, 247:2025
5. Conaglen PD, Laurenson IF, Sergeant A, Thorn SN, Rayner A, Stevenson J. Systematic review of tattoo-associated skin infection with rapidly growing mycobacteria and public health investigation of a cluster in Scotland, 2010. Euro Surveill. 2013; 18:20553
6. Edwald, P.W: Guarding against the most dangerous emerging pathogens: insights from evolutionary biology. Emerging Infectious Dis. 1996, 2:245
7. Holland, J.J. The origin and evolution of viruses. En: "Topley & Wilson's Microbiology and Microbial Infections" 9th ed. Vol. 1. Virology. London, Arnold, 1998, p.p. 11-21
8. Holmes, A. y cols: Climate change and human health, impacts, vulnerability and mitigation. Lancet 2006, 367:2101.
9. K.F. Kiple. The Cambridge World History of Human Disease. Cambridge, Cambridge University Press, 1993 Krause, RM.: "Emerging Infections" Academic Press, 1998.
10. Koenig E. Acute chickungunya: emergence of a new, viral pathogen in the Caribbean. Rev Panam Salud Pública. 2014; 36: 277-8.
11. Krause, RM.: The origin of plagues: Old and New. Science 1992, 257: 1073
12. Kumate, J. Contención, Control, Eliminación, Erradicación de las enfermedades infectocontagiosas En: "Una Visión Integradora" Universo-Vida Hombre y Sociedad. F.G. Bolivar Zapata, Pablo Rudomin.- Modulo 3 México, El Colegio Nacional, 2005. pp. 257-258
13. Kurane, Ischiro. The effect of global warming on infectious diseases. Osong Public Health Res Perspect . Diciembre 2010; 1 (1): 4–9.
14. Levy P. Innate immunity of the newborn: Basic mechanisms and clinical correlates. Nature Revies/Immunology 2007; 7: 379-390.
15. Spencer CT, Vasconcelos JR, Thornburg NJ, Zimmer SL. Advances in Emerging and Neglected Infectious Diseases 2018. Biomed Res Int. 2018 Jul 15; 2018:4619282.
16. The Lancet. Ebola: protection of health-care workers. Lancet. 2015; 384 (9961): 2174.
17. Waits A, Emelyanova A, Oksanen A, Abass K, Rautio A. Human infectious diseases and the changing climate in the Arctic. Environ Int. 2018; 121(Pt 1):703-713.
18. Wikan N, Smith DR. Zika virus: history of a newly emerging arbovirus. Lancet Infect Dis. 2016; 16(7):e119-e126.
19. W.R. Dowdle, D.R. Hopkins. The Eradication of Infectious Diseases. New York, John Wiley & Sons, 1998.

CAPÍTULO 2.
Microbiota normal

1. Ahmad OF, Akbar A. Microbiome, antibiotics and irritable bowel syndrome. Br
2. Med Bull. 2016 ;120(1):91-99.
3. Alarcón-Cavero T, D'Auria G, Delgado-Palacios S, Del Campo-Moreno R, Ferrer Martínez M. Microbiota 59. Del Campo-Moreno R (coordinadora). Procedimientos en Microbiología Clínica. Cercenado Mancilla E, Cantón Moreno R (editores). Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). 2016.
4. Antunes-Lopes T, Vale L, Coelho AM, et al. The role of urinary microbiota in lower urinary tract dysfunction: a systematic review. Eur. Urol. Focus. 2018: S2405-4569(18)30283-9.
5. Asakawa M, Takeshita T, Furuta M, et al. Tongue microbiota and oral health status in community-dwelling elderly adultos. mSphere. 2018; 3(4): e00332-18.
6. Bell V, Ferrão J, Pimentel L, Pintado M, Fernandes T. One health fermented foods and gut microbiota. Foods. 2018; 7(12): 1-17.
7. Biagi E, Franceschi C, Rampelli S, et al. Gut microbiota and extreme longevity. Curr. Biol. 2016; 26(11): 1480-1485.
8. Blaser MJ. The microbiome revolution. J. Clin. Invest. 2014;124:4162–4165.
9. Calatayud M, Dezutter O, Hernandez-Sanabria E, Hidalgo-Matínez S, Meysman FJR, Van de Wiele T. Development of a host-microbiome model of the small intestine. FASEB J. 2018; 6:fj201801414R.
10. Castaner O, Goday A, Park YM, et al. The gut microbiome profiles in obesity: a systematic review. Int. J. Endocrinol. 2018; 2018. 4095789.
11. Clavijo V, Flóez MJV. The gastrointestinal microbiome and its association with the control of pathogens in broiler chicken production: A review. Poult. Sci. 2018; 97(3): 1006-1021.
12. Dickson RP, Erb-Downward JR, Martínez FJ, Huffnagle GB. The microbiome and the respiratory tract. Annu. Rev. Physiol. 2016; 78: 481-504.
13. Drosos I, Tavridou A, Kolios G. New aspects on the metabolic role of intestinal microbiota in the development

of atherosclerosis. Metabolism. 2015 Jan 22. pii: S0026-0495(15)00022-0. doi: 10.1016/j.metabol.2015.01.007. [Epub ahead of print] Review. PubMed PMID: 25676802.
14. Flandroy L, Poutahidis T, Berg G, et al. The impact of human activities and lifestyles on the interlinked microbiota and health of humans and of ecosystems. Sci. Total Environ. 2018; 627:1018-1038.
15. González-Rodríguez I, Ruiz L, Gueimonde M, Margolles A, Sánchez B. Factors involved in the colonization and survival of bifidovacteria in the gastrointestinal tract. FEMS Microbiol. Lett. 2013; 340:1-10.
16. Ghosh S, Kumar M, Santiana M, Mishra A, et al. Enteric viruses replicate in salivary glands and infect through saliva. Nature. 2022; 29:1-6.
17. Gudnadottir U, Debelius JW, Du J, Hugerth LW, Danielsson H, Schuppe-Koistinen I, Fransson E, Brusselaers N. The vaginal microbiome and the risk of preterm birth: a systematic review and network meta-analysis. Sci Rep. 2022, 12(1):7926.
18. Hall AB, Tolonen AC, Xavier RJ. Human genetic variation and the gut microbiome in disease. Nat. Rev. Genet. 2017; 18(11):690-699.
19. Hamonts K, Trivedi P, Garg A, et al. Field study reveals core plant microbiota and relative importance of their drivers. Environ. Microbiol. 2018, 20(1): 124-140.
20. Hand TW, Vujkovic-Cvijin I, et al., Linking the microbiota, chronic disease and the immune system. Trends Endocrinol Metab. 2016; 27(12): 831-843.
21. Harris-Tryon TA, Grice EA. Microbiota and maintenance of skin barrier function. Science. 2022, 376(6596):940-945.
22. Hoffmann DE, Palumbo FB, Ravel J, Rowthorn V, von Rosenvinge E. A proposed definition of microbiota transplantation for regulatory purposes. Gut Microbes. 2017; 8(3): 208-213.
23. Jinlan W, Jianqing F, Yongbao Z, Dandan L, Jianing W, Weiwei C. Diversity and Biogeography of Human Oral Saliva Microbial Communities Revealed by the Earth Microbiome Project. Front Microbiol. 2022; 13 (931065): 1-9.
24. Kim AJ, Lo AJ, Pullin DA, Thornton-Johnson DS, Karimbux NY. Scaling and root planing treatment for periodontitis to reduce preterm birth and low birth weight: a systematic review and meta-analysis of randomized controlled trials. J. Periodontol. 2012;83:1508-1519.
25. Kline KA, Lewis AL. Gram-Positive Uropathogens, Polymicrobial Urinary Tract Infection, and the Emerging Microbiotaof the Urinary Tract. Microbiol. Spectr. 2016: 4(2).
26. Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology. 2014;146:1489-1499.
27. Lederberg J. Infectious history. Science. 2000;288:288-293.
28. Lederberg J. The Nobel Prize lectures. http://www.nobelprize.org/nobel_prizes/ medicine/laureates/1958/lederberg_lecture.pdf.
29. Lloyd-Price J, Makurkar A, Rahnavard G, et al. Strains, functions, and dynamics in the expanded human Microbiome project. Nature. 2017; 550(7674): 61-66.
30. Ma B, Forney LJ, Ravel J. Vaginal microbiome: rethinking health and disease. Annu. Rev. Microbiol. 2012;66:371-389.
31. Morad A, Cornu F, Dufour JC, Tsimaratos M, Lagier JC, Raoult D. Human bacterial repertoire of the urinary tract: a potential paradigm shift. J. Clin. Microbiol. 2018: JCM.00675-18.
32. Mulligan CM, Friedman JE. Maternal modifiers of the infant gut microbiota: metabolic consequences. J. Endocrinol. 2017; 235(1): R1-R2.
33. Muñoz-Garach A, Diaz-Perdigones C, Tinahones FJ. Gut micobiota and type 2 diabetes mellitus. Endocrinol. Nutr. 2016; 63(10): 560-568.
34. Passos MDCF, Moraes-Filho JP. Intestinal microbiota in digestive diseases. Arq. Gastroenterol. 2017; 54(3): 255-262.
35. Pickard JM, Zeng MY, Caruso R, Nínez G. Gut microbiota: Role in pathogen colonization, immune responses, and inflammatory disease. Immunol. Rev. 2017; 279(1): 70-89.
36. Podolsky SH. Metchnikoff and the microbiome. Lancet 2012;380:1810–1811.
37. Proctor DM, Relman DA. The landscape ecology and microbiota of the human nose, mouth, and throat. Cell Host & Microbe. 2017; 21: 421-432.
38. Rajakovich LJ, Balskus EP. Metabolic functions of the human gut microbiota: the role of metalloenzymes. Nat. Prod. Rep. 2018; Nov 19.
39. Rashed R, Valcheva R, Dieleman LA. Manipulation of Gut Microbiota as a Key Target for Crohn's Disease. Front Med (Lausanne). 2022; 16(887044): 1-18.
40. Relman DA. The human microbiome and the future practice of medicine. JAMA. 2015; 314(11): 1127-1128.
41. Ribera-Casado JM. Centenario de Elie Metchnikoff. Educ. Med. 2017; 18: 136-143.
42. Saulnier DM, Riehle K, Mistretta TA, et al. Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome. Gastroenterology. 2011;141:1782-1791.
43. Schooley RT. The human microbiome: implications for health and disease, including HIV infection. Top. Antivir. Med. 2018; 26(3): 75-78.
44. Song JH, Kim YS. Recurrent Clostridium difficile infection: risk factors, treatment, and prevention. Gut Liver. 2018; 30: 1-9.
45. Stricker S, Hain T, Chao CM, Rudloff S. Respiratory and Intestinal Microbiota in Pediatric Lung Diseases-Current Evidence of the Gut-Lung Axis. Int J Mol Sci. 2022; 23(12):6791. doi: 10.3390/ijms23126791.
46. Talbot TR. Surgical site infections and antimicrobial prophylaxis. En: Bennett JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 8th Edition, Saunders Elsevier Inc, Philadelphia, PA. USA. 2015;3492-3504.
47. Tuniyazi M, Li S, Hu X, Fu Y, Zhang N. The Role of Early Life Microbiota Composition in the Development of Allergic Diseases. Microorganisms. 2022;10(6): 1-17.
48. Ubeda C, Djukovic A, Isaac S. Roles of the intestinal microbiota in pathogen protection. Clin. Transl, Immunology. 2017; 6(2): e128.
49. Unger SA, Bogaert D. The respiratory microbiome and respiratory infections. J. Infect. 2017; 74 Suppl1: S84-S88.
50. Verma D, Garg PK, Dubey AK. Insight into the human oral microbiome. Arch. Microbiol. 2018: 1-16. doi. org/10.1007/s00203-018-1505-3.
51. Wampach L, Heintz-Buschart A, Hogan A, et al. Colonization and succession with the human gut microbiome by Archaea, Bacteria, and Microeukaryotes during the first year

of life. Front. Microbiol. 2017; 8:738: 1-21.
52. Wang L, Llorente C, Hartmann P, Yang AM, Chen P, Schnabl B. Methods to determine intestinal permeability and bacterial translocation during liver disease. J. Immunol. Methods. 2015 Jan 13. pii: S0022-1759(15)00005-8. doi: 10.1016/j.jim.2014.12.015. PubMed PMID: 25595554.
53. Wilson MT, Hamilos DL. The nasal and sinus microbiome in health and disease. Curr. Allergy Asthma Rep. 2014; 14: 485-499.
54. Wylie KM, Mihindukulasuriya KA, Zhou Y, *et al*. Metagenomic analysis of double-stranded DNA viruses in healthy adults. BMC Biology. 2014, 12:71.
55. Yamashita Y, Takeshita T. The oral microbiome and human health. J. Oral Sci. 2017. 59(2): 201-206.
56. Yu G, Gail MH, Klepac-Ceraj V, et al., Association between upper digestive tract microbiota and cancer-predisposing states in the esophagus and stomach. Cancer Epidemiol. Biomarkers Prev. 2014; 23(5): 735-41.
57. Zhang H, Zhang Z, Liao Y, Zhang W, Tang D. The Complex Link and Disease Between the Gut Microbiome and the Immune System in Infants. Front Cell Infect Microbiol. 2022, 15(924119) 1-10.

CAPÍTULO 3.
Mecanismos patogénicos

1. Abel L., Alcaı A., Schurr E., The dissection of complex susceptibility to infectious disease: bacterial, viral and parasitic infections. Current Opinion in Immunology 2014, 30:72–78
2. Alpuche-Aranda C.M., Racoosin E. Z., Swanson J.A., Miller S.I.,: *Salmonella* stimulate macrophage macropinocytosis and persist within spacious phagosomes. *J. Exp. Med.*, 1994, 179: 601.
3. Baxt L.A., Garza-Mayers A.C., Goldberg M.B., Bacterial Subversion of Host Innate Immune Pathways. SCIENCE, 2013; 340:697-701.
4. Bacterial Pathogenesis, a molecular approach edited by Brenda A. Wilson, Abigail A. Salyers, Dixie E. Whitt, Malcom E. Winkler, ASM press, Third Edition, 2010.
5. Bullock, W.E.: Anergy and infection. En: "*Advances in Internal Medicine*", 1976, Vol. 21, p. 149.
6. Carpenter D., Taype C., Goulding J., Levin M., Eley B., Suzanne Anderson S., y col. CCL3L1 copy number, CCR5 genotype and susceptibility to tuberculosis. BMC Medical Genetics 2014, 15:5.
7. Change, T.W: Recurrent viral infection (reinfection). *N. Eng. J. Med.*, 1971, 284: 765.
8. Cox, F.E.G.: How parasites evade the immune response. *Immunol. Today*, 1986, 5: 29.
9. C Y Chieng C, Kong Q, S Y Liou N, Khasriya R, Horsley H. The clinical implications of bacterial pathogenesis and mucosal immunity in chronic urinary tract infection. Mucosal Immunol. 2023:S1933-0219(22)01768-8.
10. Desselberger U. Rotavirus. Review. Virus Research, 2014; 190: 75–96.
11. Deya,B., Bishaia W.R., Crosstalk between Mycobacterium tuberculosis and the host cell. Seminars in Immunology 2014;26: 486–496.
12. Finlay, B., Falkow, S.: Common themes in microbial pathogenicity. *Microbiol. Rev.*, 1989, 53: 210.
13. Hagbom M., Sharma S., Lundgren O., Svensson L. Towards a human rotavirus disease model. Current Opinion in Virology 2012, 2:408–418Haraga A. Maikke B. Ohlson M.B., Miller S.I. *Salmonella* interplay with host cell. Nature Review Microbiology, 2008; 6:53-66.
14. Hodges K., Gill R. Infectious diarrea: Cellular and molecular mechanisms. Gut Microbes, 2010;1; 4-21.
15. Lieberman LA. Outer membrane vesicles: A bacterial-derived vaccination system. Front Microbiol. 2022;13:1029146.
16. MacLeod, C.B. y Bernheimer, A.W.: Pathogenic properties of bacteria. Tomado de: *Bacterial and Mycotic Infections of Man*. 4a. ed. Filadelfia, J.B. Lippincott Co., 1965, p. 146.
17. Mims, C.A.: The pathogenesis of infectious diseases 3rd. ed. *Academic Press New York*, 1987.
18. Organización Mundial de la Salud: Pathogenic mechanisms in dengue haemorrhagic fever: report of an international collaborative study. *Bull. WHO*, 1973, 48: 117.
19. Petri W.A., Mann B.J., Houston C. Microbial Adherence in Principles and Practices of Infectious Diseases edit by Mandel, G.L., Bennett, J.E., Dolin, R. Churchill Livingston, 7th edición, New York, 2010, pp 1989-2010.
20. Relman D.A., Falkow S. A molecular perspective of Microbial Pathogenicity, in Principles and Practices of Infectious Diseases edit by Mandel, G.L., Bennett, J.E., Dolin, R. Churchill Livingston, 7th edición, New York, 2010, pp 1989-2010.
21. Santos J.I., Shigeoka A.O., Hill H.R.: Strain differences in virulence of Group B streptococci. *Pediatr. Res.*, 1982, 16: 347.
22. Sarantis H., Grinstein S. Subversion of Phagocytosis for Pathogen Survival. Cell Host & Microbe , 2012 12.
23. Schwab, J.H.: Suppression of the immune response by microorganisms *Bact. Revs.*, 1975, 39: 121.
24. Torres, L.J., Carreño, B., Muñoz, O.: Producción de toxinas A y B por cepas de Clostridium difficile aisladas
25. de lactantes y adultos. *Arch. Invest. Med.*, 1985, 16: 119.
26. Young, J.D., Cohn, Z.: Cell mediated killing: a common mechanism? *Cell*, 1986, 46: 641.

CAPÍTULO 4.
Mecanismos defensivos

1. Abraham, S.N., Beachey, E.H., Simpson, W.A.: Adherence of *Streptococcus pyogenes, Escherichia coli,* and *Pseudomonas aeruginosa* to fibronectin-coated and uncoated epithelial cells. Infect. Immun. 1983;41: 1261-1268.
2. Arbo, A., Santos, J.I.: Diarrheal diseases in the immunocompromised host. *Pediatr. Infect. Dis. J.*, 1987, 6:849.
3. Arellano, J., Granados, J., Pérez, E., Félix, C., Kretschmer, R.: HLA, complotipos y absceso hepático amibiano en mestizos mexicanos. *Arch. Invest Med* 1990;21(supl 1):11.
4. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell. 2014;157:121-41
5. Berger Abi.: Th1 and Th2 responses: what are they? BMJ 2000;321:424.
6. Beutler, B: Innate Immunity: an overview. *Mol. Immunol,* 2004;40:845-859.

7. Bogdan, C.: Nutric oxide and the immune response. *Nature Immunol.* 2001;2:907-916.
8. Brandtzael, P.: Immune functions of human nasal mucosa and tonsils in health and disease. En: Bienenstock, J.: "Immunology of the lung and upper respiratory tract". *McGraw Hill*, Ontario, Canada, 1984: p.28.
9. Burke, F., Naylor, M.S., Davies, B., Balkwill, F.: The cytokine wall chart. *Immunol. Today*, 1993;14:165.
10. Cannon, J.L., Papafragkou, E., Park, G.W., Osborne, J., Jaykus, L.A., Vinjé, J.: Surrogates for the study of norovirus stability and inactivation in the environment: A comparison of murine norovirus and feline calicivirus. J. Food. Prot. 2006;69:2761-2765.
11. Chromek, M., Slamova, Z., Bergman, P., Kovács. L., Podracká, L., Ehrén, I., Hökfelt, T., Gudmundsson, G.H., Gallo, R.L., Agerberth, B., Brauner, A.: The antimicrobial peptide cathelicidin protects the urinary tract against bacterial infection. *Nature Med.,* 2006,12:636-341.
12. Clardy, Ch. W., Edwards, K.M., Gay, J.C.: Increased susceptibility to infection in hypothermic children. Possible role of acquired neutrophil dysfunction. *Pediatr. Infect. Dis. J.*, 1985, 4:379.
13. Divangahi M, Aaby P, Khader SA.:Trained immunity, tolerance, priming and differentiation: distinct immunological processes. Nat Immunol 2021;22:2-6
14. Du Clos, T.W.: Function of C-reactive protein. Ann. Med. 2000;32:274-8.
15. Frank, M.M.: Complement in the pathophysiology of human disease. *N. Engl. J. Med.*, 1987;316:1525.
16. Flajnik, M.F., Di Pasquiero, L.: Evolution of inmate and adaptive immunity: can we draw a line? *Trends in Immunology,* 2004;25:640-643.
17. Freedberg DE, Lamousé-Smith ES, Lightdale JR.: Use of Acid Suppression Medication is Associated With Risk for C. difficile Infection in Infants and Children: A Population-based Study. Clin Infect Dis 2015; 61:912.
18. Golassa L, Amenga-Etego L, Lo E, Amambua-Ngwa A.: The biology of unconventional invasion of Duffy-negative reticulocytes by Plasmodium vivax and its implication in malaria epidemiology and public health. Malar J. 2020;19:299.
19. Guthrie LA, McPhail LC, Henson PM, Johnston RB Jr.: Priming of neutrophils for enhanced release of oxygen metabolites by bacterial lipopolysaccharide. Evidence for increased activity of the superoxide-producing enzyme. J Exp Med 1984;160:1656-1671.
20. Hartshorn, K.L., Crouch, E.C., White, M.R., Eggleton, P., Tauber, A.I., Chang, D., Sastry, K.: Evidence for a protective role of pulmonary surfactant protein D(SP-D) against influenza A viruses. *J. Clin. Invest*. 1994;94:311-319.
21. Hoffmann J, Akira S.: Innate immunity. Curr Opin Immunol. 2013;1:1-3.
22. Hosea, S.W., Brown, E.J., Hamburger, M.I., Frank, M.I.M.: Opsonic requirements for intravascular clearance after splenectomy. *N. Engl. J. Med.* 1981;304:245
23. Ley RE, Peterson DA, Gordon JI.: Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell. 2006a; 124:837–848.
24. Mackaness GB.: The influence of immunologically committed lymphoid cells on macrophage activity in vivo. J Exp Med 1969; 129:973-992
25. Mantovani A, Netea MG.: Trained Innate Immunity, Epigenetics, and Covid-19. N Engl J Med 2020; 383:1078-1080
26. Netea MG, Domínguez-Andrés J, Barreiro LB.: Defining trained immunity and its role in health and disease. Nat Rev Immunol 2020; 20:375-388
27. Netea MG, Quintin J, van der Meer JW.: Trained immunity: a memory for innate host defense. Cell Host Microbe 2011; 9:355-361
28. Yang, D., Biragyn, A., Hoover, D.M., Lubkowski, J., Oppenheim, J.J.: Multiple roles of antimicrobial defensins cathelicidins and eosinophil-derived neurotoxin in host defense. *Ann. Rev. Immunol*. 2004;22:181-215.
29. Yang, D., Biragyn, A., Kwak, L.W., Oppenheim, J.J., Mammalian defenses in immunity: more than just microbicidal. *Trends Immunol.*, 2002;23:291-296.
30. Macpherson, A.J., Geukin, M.B., McCoy, K.D.: Immune responses that adapt the intestinal mucosa to commensal intestinal bacteria. Immunology. 2005;115:153-162.
31. MacLeod, H., Wetzler, L.M.: T Cell Activation by TLRs: A Role for TLRs in the Adaptive Immune Response. *Sci. STKE* 2007, pe48 (2007).
32. Mandell, G.L., Bennett J.E., Dolin, R. Eds. *Principles and practice of Infectious Diseases*. Philadelphia. Churchill Livingstone. 7th Edition, 2010.
33. Matsushita, M., Fujita, T.: Activation of the classical complement pathway by mannose-binding protein in association with a novel Cs like serine protease. *J. Exp. Med.*, 1992;176:1497-1502.
34. Matsushita, M., Endo, Y., Fujita, T.: MASP1 (MBL-associated serine protease 1). *Immunobiology,* 1998;199:340-347.
35. Medzhitov, R., Janeway Jr, C. Innate Immunity. *N. Engl. J. Med.*, 2000;343:338-344.
36. Mims, C.A.: The pathogenesis of infectious diseases. 3rd ed. Academic Press, Grune and Stratton, London and New York, 1987.
37. Muraille, E., Leo, O., Moser, M.: Th1/Th2 Paradigm Extended: Macrophage Polarization as an Unappreciated Pathogen-Driven Escape Mechanism? *Front. Immunol.* 2014;5:603.
38. O´Neill, L., Golenbock, D., Bowie, A.G., The history of Toll-like receptors- redefining innate immunity, *Nature Rev. Immunol.* 2013;13:453-460.
39. Peltola, V.T., McCullers, J.A.: Respiratory viruses predisposing to bacterial infections: role of neuraminidase. *Pediatr. Infect. Dis. J.* 2004;23(1 Suppl):S87-97.
40. Rot, A., von Adrian, U.H.: Chemokine grammar for immune cells, *Ann. Rev. Immunol*. 2004;22:891-928.
41. Santos, J.I.: Infección y la respuesta immune. En: Patiño, J. F. (Ed): "Infección" 1a. ed. Bogotá Colombia, 1989, p.69.
42. Schwartz, R.S.: Diversity of the immune repertoires and immunoregulation. *N. Eng J. Med.*, 2003;348:1017-1025.
43. Simms, H.H., Frank, M.M., Quinn, T.C., Holland, S., Gaither, T.A.: Studies on phagocytes in patients with acute bacterial infections. J. Clin. Invest. 1989;83:252-260.
44. Stevens, L. E., Clemmer, T. P., Miya, F., Robbins, L.: Fibronectin in severe sepsis. *Surg. Gyn. Obstet.*, 1986;162:222.
45. Takeda, K., Tsumeyasu, K; Akira, S.: Toll like receptors. *Ann. Rev. Immunol.*, 2003, 21: 335-376.
46. Tracey, K.J, Cerami, A.: Tumor necrosis factor. A pleiotropic cytokine and therapeutic target, *Ann. Rev. Med.* 1994;45:491-503 .
47. Turner, M.W.: Mannose. binding lectin.: the pluripotent molecule of the innate immune system, *Immunol. Today.* 1996;17:532-539.

48. Veldhoen M. The role of T helper subsets in autoimmunity and alergy. *Curr. Opin. Immunol.* 2009;21:606.
49. Waldman, R. H., Ganguly, R.: Immunity to infections on secretory surfaces. *J. Infect. Dis.*, 1974;130:419.
50. Walker,W.A., Isselbacher, K. J.: Intestinal antibodies. *N. Engl. J. Med.*, 1977, 297:767.
51. Yokoyama, W.M., Kim, S., French, A.R.: The dynamic life of natural killer cells, *Ann. Rev Immunol.* 2004;22:405-429.

CAPÍTULO 5.
Nutrición, infección e inmunidad

1. Beijer MR, Kraal G, den Haan JM. Vitamin A and dendritic cell differentiation. Immunology 2014; 142:39-45.
2. Beisel, W. R.: Magnitude of host nutritional responses to infection. *Am. J. Clin. Nutr.*, 1977; 30:1236.
3. Beisel, W. R., Wannemacher, R. W. Jr.: Gluconeogenesis, Ureagenesis, and Ketogenesis during sepsis. *JPEN*; 1980, 4:277.
4. Bendich A. Vitamins and immunity. *J. Nutr.*, 1992, 122:601.
5. Beutler, B., Mahoney, J., Letrang, N., Pekala, P., Cerami, A.: Purification of cachectin, a lipoprotein lipasa-supressing hormonal secreted by endotoxin induced raw 264.7 cells. *J. Exp. Med.*; 1985, 161:984.
6. Beutler, B., Cerami, A.: Cachectin more than a tumor necrosis factor. *N. Engl. J. Med.*; 1987, 316:379.
7. Bradley, S. F., Kauffman, C. A.: Effect of malnutrition on Salmonellosis and fever. *Infect Immun*; 1988, 56: 1000.
8. Bulla, A., Hitze, K. L.: Acute respiratory infections a review. *Bull. WHO* 1978, 58:481.
9. Conejero, R., Lorenzo, A., Arnal, F., García,J.: Significance of the changes in plasma amino-acids levels in meningococcical infection. *Care Med.*; 1987, 13:337.
10. Corman, L.: The relationship between nutrition, infection and immunity. *Med. Clin. North Am.* 1985, 69-.519.
11. Chandra R. K. : Protein-energy malnutrition and immunological response. *J. Nutr.* 1992, 122:597.
12. Christou, N. V.: Host defence mechanism in surgical patients: a correlative study of the delayed hypersensivity skin test response granulocyte function and sepsis in 2202 patients. *Can. J. Surg*. 1983; 28:39.
13. Djukic M, Onken ML, Schütze S, et al. Vitamin d deficiency reduces the immune response, phagocytosis rate, and intracellular killing rate of microglial cells. Infect Immun. 2014;82:2585-94.
14. De Francisco A., Chakraborty J., Chowdhury H.R., Yunus M., Baqui A. H., Siddique A. K., Sack R. B.: Acute toxicity of vitamin A given with vaccines in infancy. *Lancet*, 1993, 342:526.
15. Delrue C, Speeckaert R, Delanghe JR, Speeckaert MM. Vitamin D Deficiency: An Underestimated Factor in Sepsis? Int J Mol Sci. 2023;24(3):2924.
16. Faggioni R, Feingold KR, Grunfeld C . Leptin regulation of the immune response and the immunodeficiency of malnutrition. Faseb J 2001;15: 2565–2571
17. Garret WS. Kwashiorkor and the gut microbiota. N Engl J Med. 2013;368(18):1746-7.
18. Gómez, F:. Chronic severe infantile malnutrition. *Ann. N. Y. Acad. Sci.*; 1956, 69:969.
19. Gore, N. S.: Measles, immunity, and malnutrition. En Watson, R. R. (Ed.): *Nutrition disease resistence and immune function*. New York, Marcel Dekker; 1984-1 p. 113.
20. Grazioso, C. F., Isalgué, M., Ramírez, I., Ruz, M., Solomons N. W.: The effect of zinc supplementation on parasitic reinfestation of Guatemalan schoolchildren. *Am. J. Clin. Nutr.*; 1993; 57-.673.
21. Gro Harlem, B.: Nutrition and infection: malnutrition and mortality in public health. *Nutr Rev.*; 2000, 58 (2, part II): S1-S4.
22. Hatchigian, E. A., Santos, J. I.: Vitale: Enhanced phagocytosis with Vitamin A during experimental Salmonella Infection. *Soc. Exp. Biol. Med.*; 1989, 191:47.
23. Ijaiya MA, Anjorin S, Uthman OA. Individual and contextual factors associated with childhood malnutrition: a multilevel analysis of the double burden of childhood malnutrition in 27 countries. Glob Health Res Policy. 2022 ;7(1):44.
24. Kane AV, Dinh DM, Ward HD. Childhood malnutrition and the intestinal microbiome. Pediatr Res. 2015; 77: 256-62.
25. Keusch, G. T., Cruz, J., Torun, B., Urrutia, J. I., Smith, H. Jr., Flores, R., Goldstein, A. L.: Immature circulating limphocytes in malnourished Guatemalan Children. *J. Pediatr. Gastroenterol.*; 1987, 6:387.
26. Keusch, G. T., Douglas, S. D., Hammen, G., Braden, K.: Antibacterial functions of macrophages in experimental proteincalorie malnutrition. II. Celular and humoral factors for chemotaxis, phagocytosis and intracellular bactericidal activity. *J. Infect. Dis.*; 1978, 138:134.
27. King C, Siddle M, Adams O, Ahmar S, Ahmed T, Bakare AA, et al; INSPIRING Consortium. Prevalence of pneumonia and malnutrition among children in Jigawa state, Nigeria: a community-based clinical screening study. BMJ Paediatr Open. 2022 Oct; 6(1): e001640.
28. Liao SL, Hua MC, Tsai MH, Su KW, Lin C, Yao TC, et al . Association between Serum Zinc and Toll-like-Receptor- Related Innate Immunity and Infectious Diseases in Well-Nourished Children with a Low Prevalence of Zinc Deficiency: A Prospective Cohort Study. Nutrients. 2022; 14(24):5395.
29. Long KZ, Garcia C, Ko G, Santos JI, Al Mamun A, Rosado JL, DuPont HL, Nathakumar N. Vitamin A modifies the intestinal chemokine and cytokine responses to norovirus infection in Mexican children. J Nutr. 2011; 141: 957-63.
30. Long KZ, Santos JI, Rosado JL, Estrada-Garcia T, Haas M, Al Mamun A, DuPont HL, Nanthakumar NN. Vitamin A supplementation modifies the association between mucosal innate and adaptive immune responses and resolution of enteric pathogen infections. Am J Clin Nutr. 2011; 93: 578-85.
31. Long, K and Santos JI. Vitamins and the regulation of the immune response. Ped Infect Dis J 18: 223, 1999.
32. Long KZ, Santos JI, Rosado JL, et al. Impact of Vitamin A on selected gastrointestinal pathogen infections and associated diarrheal episodes among children in Mexico City, Mexico. JID 2006; 194: 1217-1225
33. Long KZ, Estrada T, Santos JI, et al. The impact of vitamin A supplementation on the intestinal immune response in Mexican children is modified by pathogen infections and diarrhea. J of Nutr. 2006; 136: 1365-1370
34. Maki P. A., Newberne P. M.: Dietary lipids and immune function. *J. Nutr.*, 1992, 122:610.
35. Mata, L. J., Urrutia, J. J., Albertazzi, C., Pellecer, O. & Arellani, B. (1972) Influence of recurrent infections on nutrition

and growth of children in Guatemala. Am. J. Clin. Nutr. 25:1267-1275.
36. Matarese G, Moschos S, Mantzoros CS Leptin in immunology. J Immunol 2005; 174: 3137–3142.
37. McCarter MD, Naama HA, Shou J, Kwi LX, Evoy DA, et al. Altered macrophage intracellular signaling induced by protein-calorie malnutrition. Cell Immunol 1998; 183: 131–136.
38. Nikbin S. M. : Vitamin/mineral supplementation , the aging immune response and risk of infection. *Nutr. Rev.*, 1993, 51:106.
39. Ongaskul, M., Sirisinha, S., Lamb, A. J.: Impaired blood clearance of bacteria and phagocytlc activity in vitamin A deficient rats (41999). *Proc. Soc. Exp. Biol. Med.*; 1985, 178:204.
40. Purtilo, D. T., Connor, D. H.: Fatal infection in protein calorie malnourished children with thymolynphatic atrophy. *Arch. Dis. Child.*; 1975, 50:149.
41. Rall, L. C., Meydani , S. N.: Vitamin B6 and Immune Competence. *Nutr. Rev.*; 1993, 51:217.
42. Santos, J. I., Nutrition, infection, and immunocompetence. Infectious Disease. Clinics of North America 1994.8:243-267.
43. Sever, J. L., Fuccillo, D. A., Ellemberg, J., Gilkeson, M. R.: Infection and low birth weight on industrialized society. *Am. J. Dis. Child.*; 1975, 129: 557.
44. Schopfer, K., Douglas, S. D.: Neutrophil function in children with Kwashiorkor. *J. Lab. Clin. Med.*; 1976, 88:450.
45. Sherman A. R.: Zinc, copper and iron nutriture and immunity. *J. Nutr.*; 1992, 122:604.
46. Shi Y, Lei Q, Liu H, Han Q. The role of vitamin A and zinc supplementation in pediatric pneumonia: A protocol for systematic review and network meta-analysis. Medicine (Baltimore). 2022;101(51): e32183.
47. Shigeoka, A. O., Charette, R. P., Wyman, M. L., Hill H. R.: Defective oxidative metabolic responses of neutrophils from stressed neonates. *J. Pediatr.*, 1981, 98: 392.
48. Shenai, J. P., Kennedy, K. A., Chytil, F., Atahlman, M. T.: Clinical trial of vitamin A supplementation in infants susceptible to bronchopulmonary dysplasia. *J. Pediatr.*; 1987, 11: 269.
49. Smith MI, Yatsunenko T, Manary MJ, et al. Gut microbiomes of Malawian twin pairs discordant for kwashiorkor. Science 2013; 339: 548-554.
50. Smythe PM Changes in intestinal bacterial flora and role of infection in Kwashiorkor. Lancet, 2 (7049) (1958 Oct 4), pp. 724-72.
51. Stansfield S. K., Pierre-Louis M, Lerebours G, Augustin A.: Vitamin A supplementation and increased prevalence of chilhood diarrhoea and acute respiratory infections. *Lancet*, 1993, 342: 578.
52. Stronk, R. C., Murrow, B. W., Thilo, E., Kunke, K. S., Johnson, E. G.: Macrophages function in infants receiving intralipid by low - dose intermittent administration. *J. Pediatr.*, 1985, 106:640.
53. Suskind, R.: The immune response in the malnourished child. En: Watson, R. R.(Ed.): *Nutrition, Resistance, and Immune Function*. Marcel Dekker, Inc. New York. 1984; p. 149-163.
54. Tilg H, Moschen AR. Food, Immunity, and the Microbiome. Gastroenterology. 2015 Jan 6. pii: S0016-5085(15)00012-8.
55. Toole, M. S., Waldrnan, R. I.: An analysis of mortality trends among refugee populations in Somalia. Sudan. *Bull. WHO*; 1988, 66:237.
56. Tracey, K. J., Lowry, S. F., Cerami, A.: Cachectin: A Hormone that trigger acute shock and chronic cachexia. *J. Infect. Dis.*; 1988, 157:413.
57. Trehan I, Goldbach HS, LaGrone LN, et al. Antibiotics as part of the management of severe acute malnutrition. N Engl J Med 2013; 368: 425-435
58. Van Molle W, Libert C How glucocorticoids control their own strength and the balance between pro- and anti-inflammatory mediators. Eur J Immunol 2005; 35: 3396–3399
59. Vaccaro JA, Qasem A, Naser SA. Folate and Vitamin B12 Deficiency Exacerbate Inflammation during Mycobacterium avium paratuberculosis (MAP) Infection. Nutrients. 2023 Jan 4; 15(2): 261.
60. Wheeler, J. G., Boyle, R. J., Abramson, J. S.: Intralipid infusion in neonates. Effects on polimorphonuclear leukocyte function. *J. Pediatr Gastroenterol. Nutr.;* 1985, 4:453.
61. Wiernik, A., Jarstrand, C., Julander, I.: The effect of intralipid on mononuclear and polymorphonuclear phagocites. *Am. J. Clin. Nutr.*; 1983, 37:256.
62. Wood, Ch., Watson, R. R.: Interrelationships among Nutritional Status, Cellular Immunity, and Cancer. En: Watson, R. R.*(Ed.): Nutrition,* P.M. *Resistance, and Immune Function*. Marcel Dekker, Inc. New York; 1984.

CAPÍTULO 6.
El laboratorio en el diagnóstico de enfermedades infecciosas

1. Bourbeau PP, Ledeboer NA. Automation in clinical microbiology. J Clin Microbiol 2013; 51:1658-65.
2. Burillo A, Bouza E. Use of rapid diagnostic techniques in ICU patients with infections. BMC Infect Dis. 2014; 14: 593.
3. Campbell CK, Holmes AD, Davey KG, Szekely A, Warnock DW. Comparison of a new chromogenic agar with the germ tuve method for presumptive identification of Candida albicans. Eur J Clin Microbiol Infec Dis. 1998;17:367-368
4. Castellanos-Cruz MC, Mejía-Albarrán ME, Jiménez-Tapia Y, Pichardo-Villalón L, Franco-Hernández MI, Alcázar-López V, De León-Ham A, Tapia-Madrigal L, Hernández-Sánchez J, López-Martínez B, Parra-Ortega I. Identificación y susceptibilidad bacteriana utilizando equipo automatizado Vitek 2 XL en el laboratorio del Hospital Infantil de México. Rev Latinoam Patol Clin Med Lab 2017;64: 50-53
5. CLSI. User Protocol for Evaluation of Qualitative Test Performance; Approved Guideline—Second Edition. CLSI, document EP12-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
6. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; Approved standard. Twenty-third informational supplement. CLSI document M100-S23.Wayne, PA: Clinical and Laboratoy Standards Institute (CLSI); 2013.
7. Díaz PH, Solórzano SF, Ruiz RA, Sánchez HG, Rosas MS, Aleman VP, Torres FJ, Muñoz HO. Indirect immunofluorescent assay (IFA) in buffy-coat, a rapid diagnostic test for invasive candidiasis. *Arch Med Res* 1995; 26 (Suppl): S41-S46.
8. Eisenstein BI. The polymerase chain reaction. A new method of using molecular genetics for medical diagnosis. *N Engl J Med* 1990; 322: 178- 183.

9. Espy MJ, et al. Real-Time PCR in Clinical Microbiology: Applications for Routine Laboratory Testing. Clin Microbiol Rev 2006: 19; 165-256
10. Fournier PE, Drancourt M, Colson P, Rolain JM, La Scola B, Raoult D. Modern clinical microbiology: new challenges and solutions. Nat Rev Microbiol 2013; 11:574-85.
11. Fredricks DN, Relman DA. Application of polymerase chain reaction to the diagnosis of infectious diseases. *Clin Infect Dis* 1999; 29: 475-488.
12. Friedman AD, Ray CG. Rapid laboratory diagnosis of infections. *Pediatr Infect Dis* 1982; 1: 366
13. Hill HR, Matsen JM. Enzyme-linked immunosorbent assay and radioimmunoassay in the serologic diagnosis of infectious diseases. *J Infect Dis* 1983; 147: 258
14. Gutiérrez Jiménez J et al. Malnutrition and the presence of intestinal parasites in children from the poorest municipalities of Mexico: J Infect Dev Ctries 2013; 7(10):741-747.
15. Herve E. B. Nuevas tecnologías en el diagnóstico microbiológico automatizado y algunas aplicaciones en identificación microbiana y estudio de susceptibilidad. Rev. Med. Clin.Condes-2015:26(6)753-763
16. Leven M, and Goossens H. Relevance of nucleic acid amplification techniques for diagnosis of respiratory tract infections in the clinical laboratory. *Clin Microbiol Rev* 1997; 10: 242-256.
17. Innis MA, Myambo KB, Gelfand DH, and Brow MA. DNA sequencing with *Thermus aquaticus* DNA polymerase and direct sequencing of polymerase chain reaction-amplified DNA. *Proc Natl Acad Sci* 1988; 85: 9436-9440.
18. James K. Immunoserology of infectious diseases. *Clin Microb Rev* 1990; 3: 132
19. Lewis JS, Fakile O, Foss E, Legarza G, Leskys A, Lowe K, and Powning D. Direct DNA probe assay for *Neisseria gonorrhoeae* in pharyngeal and rectal specimens. *J Clin Microbiol* 1993; 31: 2783-2785.
20. Jorgensen J, Ferraro M. Antimicrobial Susceptibility testing: A review of General Principles and Contemporary Practices. Clinical Infectious Diseases 2009; 49: 1749-55
21. Koczula KM, Gallota A, Lateral flow assays, Essays Biochem.2016;60:111-20
22. Labarca JA, Wagar EA. Grasmick AE. Kokkinos HM, Bruckner DA. Critical evaluation of a 4-week incubation for fungal cultures: isthe fourth week useful? J Clin Microbiol. 1998;36:3683-5
23. López-Martínez B, Calderón-Jaimes E, Olivar-López V, Parra-Ortega I, Alcázar-López V, Castellanos-Cruz MC y cols. Susceptibilidad antimicrobiana de microorganismos causantes de infección de vías urinarias bajas en un hospital pediátrico. Bol Med Hosp Infant Mex. 2014; 71 (6): 339-345
24. Magaña JJ, Arenas-Sordo ML, Gómez R. La electroforesis capilar como una nueva estrategia en la medicina y el diagnóstico clínico. Rev Méd Chile 2009; 137: 946-956
25. Mulder NJ, Akinola RO, Mazandu GK, Rapanoel H. Using biological networks to improve our understanding of infectious diseases. Comput Struct Biotechnol J. 2014 27; 11: 1-10.
26. Mycology Online. David Ellis. The University of Adelaide. Micosis, guías de diagnóstico y tratamiento, bancos de imágenes y otros recursos. https://www.adelaide.edu.au/mycology/
27. Pednaeult L, Campos JM, Jenson HB. Serologic Diagnosis of Infectious Diseases. En:Jenson HB, Baltimore RS (Eds.) Pediatric Infectious Diseases. Principles and practice. *Appleton and Lange*. Norwalk, Connecticut 1995: 67-93
28. Persing DH. Polymerase chain reaction: trenches to benches. *J Clin Microbiol* 1991; 29: 1281-1285.
29. Pfaller MA, and Cormican MG. Role of the microbiology laboratory in monitoring and identifying resistance: use of molecular biology. *New Horizons* 1996; 4: 361-369.
30. Procedimientos en Microbiología Clínica, Recomendaciones de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica 2006, ISBN: 84-611-3540-7
31. Reller LB, Murray PR, MacLowry JD. Blood culture II. *Cumitech 1A*. Washington D.C., American Society for Microbiology, 1982.
32. Reyes-Pérez H et al: Correlation between viral load of cytomegalovirus and tacrolimus and sirolimus levels in transplanted pediatric patients. Bol Med Hosp Infant Mex. 2016;73(1):4-9
33. Ruiz Reyes G, Ruiz Argüelles A. Fundamentos de interpretación clínica de los exámenes de laboratorio. En: Sifuentes Osornio J. Padecimientos infecciosos. Tercera edición: 2017
34. Ruppenthal RD, Souza Pereira F, Cantarelli VV, SilveiraSchrank I. Application of broad-range bacterial PCR amplification and direct sequencing on the diagnosis of neonatal sepsis. Braz J Microbiol.2005; 36 (1): 29-35.
35. Sánchez Huerta JL, Parra Ortega I, Hernández Sánchez C, Pichardo Villalón L, Cruz López A, Villanueva García D, López Martínez B, Villa Guillen M. Evaluación de una prueba de PCR múltiple para la identificación del ADN bacteriano y fúngico en el diagnóstico de sepsis neonatal. Rev Latinoam Patol Clin Med Lab 2018; 65: 167-174
36. Salomon RN. Introduction to quantitative reverse transcription polymerase chain reaction. *Diagn Mol Pathol* 1995; 4: 82-84.
37. SinghS. Beena PM. Comparatve study of different microscopic tecniques and culture media isolation of dermatophytes. Indian JMed Microbiol 2003:21:21-24
38. Sloots TP, Nissen MD, Ginn AN, Iredell JR. Rapid identification of pathogens using molecular techniques. Pathology. 2015; 47:191-8.
39. Solórzano SF, Miranda NMG, Leaños MB, Díaz PH, Palacios SG. A blood micro-culture system for the diagnosis of bacteremia in pediatric patients. *Scand J Infect Dis* 1998; 30: 481-483.
40. Srinivasan L, Harris MC. New technologies for the rapid diagnosis of neonatal sepsis. Curr Opin Pediatr. 2012; 24 (2): 165-171.
41. Tang YW, and Persing DH. Molecular detection and identification of microorganisms. En: Manual of Clinical Microbiology. Seventh edition. Murray PR (ed.). *ASM Press*; Washington, DC. 1999: 215-244.
42. Tang YW, Procp GW, and Persing DH. Molecular diagnosis of infectious diseases. *Clin Chem* 1997; 43: 2021-2038.
43. Tapia Lorena I. Laboratorio de virología en la práctica clínica. Rev. Med. Clin. Condes 2015; 26(6) 744-752
44. Tapia-Romero, Raquel, Martínez-Méndez, Laura Gricelda, Dávila-Solís, Beatriz Leticia, López-Martínez, Briceida, & Parra-Ortega, Israel. (2015). Transición parasitaria: experiencia en un hospital pediátrico de tercer nivel (1990-2010). Boletín médico del Hospital Infantil de México, 72(3), 174-180. https://dx.doi.org/10.1016/j.bmhimx.2015.06.002

45. Tenover FC, Arbeit RD, and Goering RV. How to select and interpret molecular strain typing methods for epidemiological studies of bacterial infections: a review for healthcare epidemiologists. *Infect Control Hosp Epidemiol* 1997; 18. 426-439.
46. Tschiedel E, Steinmann J, Buer J, Onnebrink JG, Felderhoff-Müser U, Rath PM et al. Results and relevance of molecular detection of pathogens by SeptiFast--a retrospective analysis in 75 critically ill children. Klin Padiatr. 2012; 224 (1): 12-16.
47. Wiedbrauk DL. Molecular methods for virus detection. *Lab Med* 1992; 23: 737-742.

CAPÍTULO 7. Sepsis

1. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022; 399(10325):629-655.
2. Balamuth F, Scott HF, Weiss SL, Webb M, Chamberlain JM, Bajaj L, et al; Pediatric Emergency Care Applied Research Network (PECARN) PED Screen and PECARN Registry Study Groups. Validation of the Pediatric Sequential Organ Failure Assessment Score and Evaluation of Third International Consensus Definitions for Sepsis and Septic Shock Definitions in the Pediatric Emergency Department. JAMA Pediatr. 2022; 176(7):672-678.
3. Chakraborty RK, Burns B. Systemic Inflammatory Response Syndrome. 2022 May 30. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–PMID: 31613449
4. Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, Machado FR, Mcintyre L, Ostermann M, Prescott HC, Schorr C, Simpson S, Wiersinga WJ, Alshamsi F, Angus DC, Arabi Y, Azevedo L, Beale R, Beilman G, Belley-Cote E, Burry L, Cecconi M, Centofanti J, Coz Yataco A, De Waele J, Dellinger RP, Doi K, Du B, Estenssoro E, Ferrer R, Gomersall C, Hodgson C, Møller MH, Iwashyna T, Jacob S, Kleinpell R, Klompas M, Koh Y, Kumar A, Kwizera A, Lobo S, Masur H, McGloughlin S, Mehta S, Mehta Y, Mer M, Nunnally M, Oczkowski S, Osborn T, Papathanassoglou E, Perner A, Puskarich M, Roberts J, Schweickert W, Seckel M, Sevransky J, Sprung CL, Welte T, Zimmerman J, Levy M. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021 Nov;47(11):1181-1247. doi: 10.1007/s00134-021-06506-y. Epub 2021 Oct 2. PMID: 34599691; PMCID: PMC8486643
5. Fernández-Sarmiento J, De Souza DC, Martinez A, Nieto V, López-Herce J, Soares Lanziotti V, et al. Latin American Consensus on the Management of Sepsis in Children: Sociedad Latinoamericana de Cuidados Intensivos Pediátricos [Latin American Pediatric Intensive Care Society] (SLACIP) Task Force: Executive Summary. J Intensive Care Med. 2022 ; 37:753-763.
6. Garza-González E, Morfín-Otero R, Mendoza-Olazarán S, Bocanegra-Ibarias P, Flores-Treviño S, Rodríguez-Noriega E, et al. (2019) A snapshot of antimicrobial resistance in Mexico. Results from 47 centers from 20 states during a six-month period. PLoS ONE 14(3): e0209865. https://doi.org/10.1371/journal.pone.0209865
7. Gharamti A, Samara O, Monzon A, Scherger S, DeSanto K, Sillau S, Franco-Paredes C, Henao-Martínez A, Shapiro L. Association between cytokine levels, sepsis severity and clinical outcomes in sepsis: a quantitative systematic review protocol. BMJ Open. 2021 ; 11(8):e048476.
8. Global report on the epidemiology and burden of sepsis: current evidence, identifying gaps and future directions. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.
9. Helguera-Repetto AC, Soto-Ramírez MD, Villavicencio-Carrisoza O, Yong-Mendoza S, Yong-Mendoza A, León-Juárez M, et al. Assessment of Health Care Exposures and Outcomes in Adult Patients With Sepsis and Septic Shock. JAMA Netw Open. 2020 Jul 1;3(7):e206004. doi: 10.1001/jamanetworkopen.2020.6004.
10. Herrera-Van Oostdam AS, Castañeda-Delgado JE, Oropeza-Valdez JJ, Borrego JC, Monárrez-Espino J, Zheng J, Mandal R, et al. Immunometabolic signatures predict risk of progression to sepsis in COVID-19. PLoS One. 2021; 16(8):e0256784.
11. Mas-Celis F, Olea-López J, Parroquin-Maldonado JA. Sepsis in Trauma: A Deadly Complication. Arch Med Res. 2021; 52:808-816.
12. Mazouri A, Avila CA, Piersigilli F, Trujillo M, Kolman S, Delgado V, et al; Global NEO-ASP Study Group. A global point prevalence survey of antimicrobial use in neonatal intensive care units: The no-more-antibiotics and resistance (NO-MAS-R) study. E Clinical Medicine. 2021; 32:100727.
13. Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet. 2020 Jan 18;395(10219):200-211.
14. Steinhagen F, Schmidt SV, Schewe JC, Peukert K, Klinman DM, Bode C. Immunotherapy in sepsis - brake or accelerate? Pharmacol Ther. 2020 Apr; 208:107476. doi: 10.1016/j.pharmthera.2020.107476.
15. Toledo-Salinas O, Sánchez-Hurtado LA, Rodríguez-Silverio J. Association of fever and antipyretic treatment with progressive organ dysfunction in sepsis: Prospective cohort. Gac Med Mex. 2021; 157(4):377-383.
16. Toshiaki Iba, Yutaka Umemura, Hideo Wada, Jerrold H. Levy. Roles of Coagulation Abnormalities and Microthrombosis in Sepsis: Pathophysiology, Diagnosis, and Treatment. Archives of Medical Research. 2021; 52: 788-797,
17. Weiss SL, Peters MJ, Alhazzani W, Agus MSD, Flori HR, Inwald DP, et al. Surviving Sepsis Campaign International Guidelines for the Management of Septic Shock and Sepsis-Associated Organ Dysfunction in Children. Pediatr Crit Care Med. 2020 Feb;21(2):e52-e106. doi: 10.1097/PCC.0000000000002198.
18. Zelellw DA, Dessie G, Worku Mengesha E, Balew Shiferaw M, Mela Merhaba M, Emishaw S. A Systemic Review and Meta-analysis of the Leading Pathogens Causing Neonatal Sepsis in Developing Countries. Biomed Res Int. 2021 Jun 5;2021:6626983. doi: 10.1155/2021/6626983.

CAPÍTULO 8. Síndrome febril

1. Andreola B, Bressan S, Callegaro S, Liverani A, Plebani M, Da Dalt L. Procalcitonin and C-reactive protein as diagnos-

tic markers of severe bacterial infections in febrile infants and children in the emergency department. Pediatr Infect Dis J 2007;26:672-7.
2. Baker MD, Bell LM, Avner JR.The efficacy of routine outpatient management without antibiotics of fever in selected infants. Pediatrics 1999;103; 627-31.
3. Benito-Fernández J, Raso SM, Pocheville-Gurutzeta I, SánchezEtxaniz J, Azcunaga-Santibañez B, Capapé-Zache S. Pneumococcal bacteremia among infants with fever without known source before and after introduction of pneumococcal conjugate vaccine in the Basque Country of Spain. Pediatr Infect Dis J 2007;26:667-71.
4. Blockmans D, Knockaert D, Maes A, De Caestecker J, Stroobants S, Bobbaers H, Mortelmans L Clinical value of [(18)F]fluoro-deoxyglucose positron emission tomography for patients with fever of unknown origin. Clin Infect Dis 2001;32:191-6.
5. Brockmann V P, Ibarra G X, Silva W I, Hirsch B T. Etiology of acute fever without source in infants consulting at an emergency department Rev Chilena Infectol 2007;24 :33-9.
6. Byington CL, Enriquez FR, Hoff C, Tuohy R, Taggart EW, Hillyard DR, Carroll KC, Christenson JC. Serious bacterial infections in febrile infants 1 to 90 days old with and without viral infections. Pediatrics 2004;113:1662-6.
7. Byington CL, Rittichier KK, Bassett KE, Castillo H, Glasgow TS, Daly J, Pavia AT. Serious bacterial infections in febrile infants younger than 90 days of age: the importance of ampicillin-resistant pathogens. Pediatrics 2003;111:964-8.
8. Craig JV, Lancaster GA, Williamson PR, Smyth RL. Temperature measured at the axilla compared with rectum in children and young people: systematic review. *BMJ* 2000; 320:1174-1178.
9. Douglas A, Thursky K, Slavin M. New approaches to management of fever and neutropenia in high-risk patients. Curr Opin Infect Dis. 2022 ;35(6):500-516.
10. Goh PL, Lee SW, Wong EH. Predictors of serious bacterial infection in children aged 3 to 36 months with fever without source. Singapore Med J 2006; 47:276-80.
11. Grace CJ, Lieberman J, Pierce K, Littenberg B. Usefulness of blood culture for hospitalized patients who are receiving antibiotic therapy. Clin Infect Dis 2001 ;32:1651-5.
12. Greenes DS, Fleisher GR. Accuracy of a noninvasive temporal artery thermometer for use in infants. Arch Pediatr Adolesc Med 2001;155: 376-81.
13. Hanjan SN, Talwar GP.. Bachur R, et al. Occult pneumonias: empiric chest radiographs in febrile children with leukocytosis. Ann Emerg Med February 1999; 33:166-73.
14. Harrison RF, Ouyang H. Fever and the rational use of antimicrobials in the emergency department. Emerg Med Clin North Am. 2013;31:945-68.
15. Isaacman DJ, Burke BLUtility of the serum C-reactive protein for detection of occult bacterial infection in children. Arch Pediatr Adolesc Med 2002 ;156:905-9.
16. Isaacman DJ, Shults J, Gross TK, Davis PH, Harper M. Predictors of bacteremia in febrile children 3 to 36 months of age. Pediatrics 2000 ;106:977-82.
17. Lehrnbecher T, Robinson PD, Ammann RA, Fisher B, Patel P, Phillips R, et al. Guideline for the Management of Fever and Neutropenia in Pediatric Patients With Cancer and Hematopoietic Cell Transplantation Recipients: 2023 Update. J Clin Oncol. 2023:JCO2202224.
18. Lee GM, Fleisher GR, Harper MB. Management of febrile children in the age of the conjugate pneumococcal vaccine: a cost-effectiveness analysis. Pediatrics 2001;108:835-44.
19. Luong Ba K, Harbarth S, Carballo S. Procalcitonin: should it be measured systemically?. Rev Med Suisse. 2013;9:1881-2, 1884-5.
20. Maayan-Metzger A, Mazkereth R, Kuint . Fever in healthy asymptomatic newborns during the first days of life. Arch Dis Child Fetal Neonatal Ed 2003;88:F312-4.
21. Mourad O, Palda V, Detsky AS. A comprehensive evidence-based approach to fever of unknown origin. Arch Intern Med 2003;163;545-51.
22. Mor M, Paz M, Amir L, Levy I, Scheuerman O, Livni G, et al. Bacterial vs viral etiology of fever: A prospective study of a host score for supporting etiologic accuracy of emergency department physicians. PLoS One. 2023;18(1):e0281018.
23. Pacifici GM, Allegaert K. Clinical pharmacology of paracetamol in neonates: a review. Curr Ther Res Clin Exp. 2014;77:24-30.
24. Pantell RH, Newman TB, Bernzweig J, Bergman DA, Takayama JI, Segal M, Finch SA, Wasserman RC. Management and outcomes of care of fever in early infancy. JAMA 2004;291:1203-12.
25. Perrott DA, Piira T, Goodenough B, Champion GD. Efficacy and safety of acetaminophen vs ibuprofen for treating children's pain or fever: a meta-analysis. Arch Pediatr Adolesc Med 2004 ;158:521-6.
26. Pulliam PN, Attia MW, Cronan KM. C-reactive protein in febrile children 1 to 36 months of age with clinically undetectable serious bacterial infection. Pediatrics 2001; 108:1275-9.
27. Richardson M, Lakhanpaul M; Guideline Development Group and the Technical Team. Assessment and initial management of feverish illness in children younger than 5 years: summary of NICE guidance. BMJ 2007;334:1163-4.
28. Sarrell EM, Wielunsky E, Cohen HA. Antipyretic treatment in young children with fever: acetaminophen, ibuprofen, or both alternating in a randomized, double-blind study. Arch Pediatr Adolesc Med 2006;160:197-202.
29. Statler VA, Marshall GS. Evaluation of Prolonged and Recurrent Unexplained Fevers. Pediatr Ann. 2018 Sep 1;47(9):e347-e353.
30. Takeda R, Mizooka M, Kobayashi T, Kishikawa N, Yokobayashi K, Kanno K, Tazuma S. Key diagnostic features of fever of unknown origin: Medical history and physical findings. J Gen Fam Med. 2017;18(3):131-134.
31. Trautner BW, Caviness AC, Gerlacher GR, Demmler G, Macias CG. Prospective evaluation of the risk of serious bacterial infection in children who present to the emergency department with hyperpyrexia (temperature of 106 degrees F or higher). Pediatrics 2006;118:34-40.
32. Vanderschueren S, Knockaert D, Adriaenssens T, Demey W, Durnez A, Blockmans D, Bobbaers H. From prolonged febrile illness to fever of unknown origin: the challenge continues. Arch Intern Med 2003;163:1033-41.
33. Whybrew K, Murray M, Morley C. Diagnosing fever by touch: observational study. *BMJ* 1998;317:321-330.
34. Wing R, Dor MR, McQuilkin PA. Fever in the pediatric patient. Emerg Med Clin North Am. 2013;31:1073-96.
35. Wright WF, Mulders-Manders CM, Auwaerter PG, Bleeker-Rovers CP. Fever of Unknown Origin (FUO) - A Call for New Research Standards and Updated Clinical Management. Am J Med. 2022; 135(2):173-178.